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Winfried Häuser1,2*, Brian Walitt3, Mary-Ann Fitzcharles4 and Claudia Sommer5Abstract
This review addresses the current status of drug therapy for the management of fibromyalgia syndrome (FMS) and
is based on interdisciplinary FMS management guidelines, meta-analyses of drug trial data, and observational
studies. In the absence of a single gold-standard medication, patients are treated with a variety of drugs from
different categories, often with limited evidence. Drug therapy is not mandatory for the management of FMS.
Pregabalin, duloxetine, milnacipran, and amitriptyline are the current first-line prescribed agents but have had a
mostly modest effect. With only a minority of patients expected to experience substantial benefit, most will
discontinue therapy because of either a lack of efficacy or tolerability problems. Many drug treatments have
undergone limited study and have had negative results. It is unlikely that these failed pilot trials will undergo
future study. However, medications, though imperfect, will continue to be a component of treatment strategy for
these patients. Both the potential for medication therapy to relieve symptoms and the potential to cause harm
should be carefully considered in their administration.The desire to take medicine is perhaps the greatest feature
which distinguishes man from animals.
Sir William Osler (1849–1919)Introduction
Roughly 2% of the developed world’s population meet ei-
ther the 1990 or 2010 American College of Rheumatology
criteria for fibromyalgia syndrome (FMS) [1-5]. Patients
with FMS report a wide array of somatic and psycho-
logical symptoms, and each contributes to a varying
degree of symptom burden and functional disability [6,7].
Many factors shape the modern practice of FMS
pharmacologic therapy. Understandably, patients seek
symptom relief, and prospective studies [8] and con-
sumer reports demonstrate considerable use of pharma-
cological and non-pharmacological therapies [9,10].
Some may even hope for complete eradication of symp-
toms, a goal that currently is mostly unattainable. Physi-
cians are trained to alleviate symptoms, using available
evidence and clinical experience, even in the absence of* Correspondence: whaeuser@klinikum-saarbruecken.de
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6 months following its publication. After this t
Attribution License (http://creativecommons.o
reproduction in any medium, provided the ora cure. Drug prescription has been the foundation of
medical care over the past several decades, driven by the
success of many pharmacologic interventions for various
medical conditions. This success has positioned drug
prescription at the center of the practice of medicine
and has become entrenched in patient expectations for
medical care [11]. Pharmaceutical companies are also
highly motivated to provide FMS patients with success-
ful, but profitable, pharmacological therapies. Identifying
an effective FMS drug would be a triumph for patients,
health-care providers, and industry alike, and a potential
financial market is valued at $1.2 billion in the US alone
[12]. Therefore, the status of FMS drug therapy reflects
the needs of these various stakeholders, and each has a
distinct agenda. In this review, we address the following
questions:
 Which drugs are considered standard for the
treatment of FMS?
 What are the potential benefits and harms of
standard treatment drugs in FMS?
 Are there any other commonly prescribed FMS
treatments whose use is supported by (limited)
evidence?
 Are there any other commonly prescribed FMS
treatments whose use is not supported by evidence?Ltd. The licensee has exclusive rights to distribute this article, in any medium, for
ime, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the treatment of FMS?
 Which drugs held promise but without success? Are
there new hopes for a ‘magic bullet’ for FMS?
 Are any particular drugs better than the others?
 What should physicians and patients be mindful of
when drug therapy is considered?
Review
Methods
Our analyses and recommendations are based on the
following sources:
a. Interdisciplinary guidelines
Interdisciplinary FMS management guidelines have re-
cently been developed in Canada [13] and Germany [14].
The German guideline was based on a systematic search
of the literature from inception to December 2010. The
strength of recommendations was developed by multiple-
step formal procedures to reach a consensus. As measure
of efficacy, standardized mean difference of drugs versus
control group in randomized controlled trials (RCTs) was
chosen for the outcomes of pain, fatigue, sleep problems,
and health-related quality of life (HRQOL) at final treat-
ment and, if available, at follow-up. Dropout rates for the
active versus control group were chosen as a measure of
tolerability. Adverse events as reported in RCTs, open-
label studies, and case reports were chosen as measure of
risks. Efficacy, tolerability, and risks and applicability of
therapies available were summarized in a balance sheet
[15,16]. Similarly, the Canadian guideline was based on a
systematic literature search directed by questions derived
from a needs assessment. The literature was evaluated for
level of evidence according to a standard method; recom-
mendations were formulated and reviewed by a multidis-
ciplinary group and, after a voting procedure, assigned a
level of recommendation [13].
b. Meta-analyses
Cochrane reviews on antidepressants [17-20] and anticon-
vulsants [21,22] in FMS were accessed. If the number of
responders (for example, 30% pain reduction) was not re-
ported, a validated imputation method to calculate pain
reduction rates from reported means and standard devia-
tions was used [20,23].
c. Observational studies
The external validity of drug therapy in FMS is severely
limited because of uniform exclusion of inflammatory
rheumatic diseases and DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition)-defined
psychological disorders from studies [16]. Therefore, we
refer to the results of FMS consumer reports [9,10], of co-
hort studies of patient databanks [24], and of administrativeclaims data [25] to better understand patterns of drug use
in the general population.
Drugs currently prescribed as standard treatment for
fibromyalgia syndrome
The tricyclic antidepressants (TCAs), particularly ami-
triptyline, were the mainstay of FMS pharmacotherapy
up to the last decade. Although amitriptyline has never
received approval for treatment of FMS, it is available in
most countries worldwide, relatively cheaply, and is ap-
proved for treatment of depression or chronic neuropathic
pain syndromes. Originally amitriptyline was thought to
act by reducing alpha intrusion into non-rapid eye move-
ment (non-REM) sleep, but the current understanding
suggests an effect on pain modulation via serotonin and
norepinephrine. Subsequent study identified the efficacy of
pregabalin (an anticonvulsant with α2-δ ligand binding) and
two newer antidepressants - the serotonin norepinephrine
reuptake inhibitors (duloxetine and milnacipran) - in relief
of FMS symptoms. All three latter agents are approved for
FMS therapy by the US Food and Drug Administration
(FDA). Pregabalin is approved for FMS therapy not only in
the US and Canada but in a number of countries in South
America, the Middle East, and Asia.
Duloxetine is approved in 25 countries besides the US,
whereas milnacipran is approved in the US, Argentina,
Australia, and South Korea. In contrast, the European
Medical Agency (EMA) denied approval of these three
drugs on the grounds that they had not shown superior-
ity to placebo in pain reduction in studies that included
European patients [17,22]. All three are approved for the
treatment of anxiety or depressive disorders or both in
some European countries.
Efficacy and tolerability
The pain-reducing benefits of pregabalin, duloxetine, and
milnacipran are minimally outweighed by side effects
(Table 1). In that only a minority of patients will experi-
ence substantial relief [17,19,20], vigilance regarding
adverse effects is required (Table 2). Most commonly,
tolerability is limited by troublesome, but generally not
serious, side effects, such as drowsiness, weight gain or
peripheral edema for pregabalin, and gastrointestinal or
cognitive intolerance for duloxetine and milnacipran.
Although life-threatening side effects such as serotonin
syndrome and liver failure with antidepressants [17] and
heart failure with pregabalin [22] are very rare, they
should be kept in mind. Pregabalin abuse has also been re-
ported in susceptible populations, leading to classification
as a Class V controlled substance in the US [26].
The benefit-risk balance seems to be modestly favor-
able for TCAs and essentially equal for selective sero-
tonin reuptake inhibitors (SSRIs) (Table 1), but the
quality of evidence for TCAs and SSRIs is relatively poor
Table 1 Thirty percent pain reduction rates in randomized controlled trials with antidepressants and pregabalin in
patients with fibromyalgia syndrome
Drug
(reference)
Number of
RCTs/participants
30% pain reduction
true drug vs.
placebo (%)
RR 30% pain
reduction
(95% CI)
Dropout rate
due to adverse
events, percentage
RR dropout rate
due to adverse events
(95% CI)
Duloxetinea [17] 5/1,884 46.8 vs. 34.0 1.33 (1.18-1.51) 18.7 vs.10.4 1.65 (1.30-2.09)
Milnacipranb [17] 5/4,110 36.4 vs. 28.1 1.38 (1.25-1.51) 21.5 vs.11.0 2.00 (1.47-2.73)
SSRIsc [20] 7/414 36.4 vs. 20.6 1.59 (1.01-2.52) 9.5 vs. 7.0 1.60 (0.84-3.04)
TCAsd [20] 9/542 48.3 vs. 27.8 1.60 (1.15-2.34) 5.2 vs. 6.5 0.84 (0.46-1.52)
Pregabaline [22] 5/3,259 40.0 vs. 29.1 1.37 (1.22-1.53) 19.4 vs. 11.0 1.68 (1.36-2.07)
aDosages 60 mg/day, 120 mg/day, and 60 to 120 mg/day flexible pooled together. bDosages 100 mg/day, 200 mg/day, and 100 to 200 mg/day flexible pooled
together. cCitalopram 20–40 mg/day, Fluoxetine 12–80 mg/day, Paroxetine 20–60 mg/day. dAmitriptyline 10–50 mg/day. eDosages 150 mg/day, 300 mg/day,
450 mg/day, 600 mg/d, and 300–450 mg/day flexible pooled together. One study with 556 participants and an enriched enrolment withdrawal design could not
be included in meta-analysis. CI, confidence interval; RCT, randomized controlled trial; RR, relative risk; SSRI, selective serotonin reuptake inhibitor; TCA,
tricyclic antidepressant.
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abalin and serotonin noradrenaline reuptake inhibitors
(SNRIs) is flawed for a number of reasons. The data on
TCAs and SSRIs are based on early studies conducted
between 1986 and 1998, generally with small sample
sizes, whereas data for pregabalin and SNRIs are more
robust, performed with much larger sample sizes in
studies designed to seek therapeutic approval conducted
between 2004 and 2010. Study design has improved con-
siderably over the years as application of rigorous scien-
tific methodology has increased [20]. Primary endpoints
have also changed with more recent attention to global
health status rather than focusing on any single particu-
lar symptom. And finally, both the placebo as well as the
nocebo (dropout) response rate have increased over time
[27,28]. Therefore, direct comparison of TCAs and
SSRIs with pregabalin or SNRIs is confounded.
Effectiveness
Although RCTs can provide discrete estimates of effect,
the effectiveness of a drug is likely best characterized by
the real-life experience provided by observational studies
in the general population, independent of industry and
reliant on clinical judgment. TCA use in patients with
newly diagnosed FMS was examined by using privately
insured US administrative claims data, covering 1999 to
2005. The mean (median) duration of the first treatment
episode was 150 (58) days, with 60.8% augmenting TCA
use with other drugs, 61.8% switching to another drug at
the end of their TCA episode, and 22.8% discontinuing
TCAs without switching [25]. Therefore, TCAs represent
limited efficacy as a single drug in the clinical setting.
Similarly, treatment information was provided in an 11-
year follow-up of about 3,123 US adult FMS patients
registered in the National Data Bank of rheumatic dis-
ease. The centrally acting agents (pregabalin, gabapentin,
duloxetine, and milnacipran) received approval during
the observation period of the study. Use rates increasedfrom 10% to 39% over the 11 years, but mean pain, fa-
tigue, and disability measurements did not change in this
study population. For patients treated with duloxetine or
milnacipran, or pregabalin, pain scores were reduced sig-
nificantly - by 0.17 (0.03, 0.30) units, an improvement of
2.8% - following the start of these drugs but with no sig-
nificant improvements in fatigue or function. These re-
sults question whether the changes attributable to use of
these agents are truly clinically meaningful. However, a
patient’s choice to continue a treatment implies some
level of satisfaction. The estimated 25th and 50th per-
centiles of time to discontinuation for centrally acting
agents were 1 and 2.5 years, respectively [24]. In a Ger-
man fibromyalgia consumer reports study, patients did
not identify any medication in the top 10 effective ther-
apies. Rather, medication therapy was only perceived as
harmful, with pregabalin identified as the 3rd, duloxetine
the 6th, and amitriptyline the 7th most harmful therap-
ies [10]. Taking all these factors and, especially, real-
world clinical observation into consideration, we con-
tend that the overall benefit of these agents remains lim-
ited for most patients.
Other commonly prescribed fibromyalgia syndrome
treatments with use supported by (more limited)
evidence
Tramadol
Tramadol, a weak μ-opioid receptor agonist and a re-
uptake inhibitor of serotonin and norepinephrine, is fre-
quently used in FMS treatment [9,10]. As this is the only
opioid medication that has been studied in FMS, it is
unfortunate that the quantity of evidence is small. Studied
in 313 patients with FMS, tramadol/acetaminophen was
superior to placebo over 12 weeks in pain reduction and
improved quality of life [29]. Sixty-nine percent of 100
patients tolerated tramadol and achieved benefit during
the open phase. The responders were randomly assigned:
after 3 weeks, tramadol was superior to placebo in the
Table 2 Summary of the US Food and Drug Administration’s contraindications and warnings of pregabalin and
antidepressants
Drug Contraindications Warnings and precautions Last update
Pregabalin 1. Known hypersensitivity to pregabalin or
any of its components
1. Suicidal behavior and ideation June 2011
2. Usage in pregnancy
3. Hypersensitivity reactions
4. Angioedema
5. Peripheral edema
6. Dizziness and sleepiness with impairment
of the ability to drive or operate machinery
7. Gynecomastia and breast enlargement
Duloxetine 1. Concomitant use of monoaminooxidase inhibitors 1. Suicidality Jan. 2010
2. Uncontrolled narrow-angle glaucoma 2. Hepatotoxicity
3. Substantial alcohol use or evidence of chronic liver damage 3. Orthostatic hypotension and syncope
4. Severe renal impairment 4. Serotonin- or neuroleptic syndrome-like reactions
5. Abnormal bleeding
6. Discontinuation syndrome
7. Activation of mania
8. Blood pressure control
9. Hyponatremia
10. Glucose control in diabetes
11. Slow gastric emptying
12. Urinary hesitation and retention
Milnacipran 1. Concomitant use of monoaminooxidase inhibitors 1. Suicidality Jan. 2009
2. Uncontrolled narrow-angle glaucoma 2. Hepatotoxicity
3. Substantial alcohol use or evidence of chronic liver damage 3. Serotonin syndrome
5. Abnormal bleeding
6. Discontinuation syndrome
7. Elevated blood pressure
8. Urinary hesitation and retention
9. Seizures
Tricyclic agents 1. Prior hypersensitization 1. Suicidality Amitriptyline
Jan. 2010
2. Concomitant use of monoaminooxidase inhibitors 2. Anxiety and insomnia
3. Acute recovery phase following myocardial infarction 3. Activation of mania/hypomania and
schizophrenia
4. Cardiovascular disorders
5. Hyperthyroid patients or those receiving
thyroid medication
6. Elective surgery
7. Elevated or lowered blood sugar
8. Impaired liver function
Serotonin reuptake
inhibitors
1. Concomitant use of monoaminooxidase inhibitors, thioridazine
and pimozide
1. Suicidality Fluoxetine
April 2011
2. Abnormal bleeding
3. Anxiety and insomnia
4. Activation of mania/hypomania Paroxetine
July 2011
5. Hyponatremia
6. Seizures
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Table 3 Drug classes that failed to show superiority over
placebo in reducing fibromyalgia syndrome symptoms
class (drug) Number of studies /participants/
duration of trial in weeks
Antiviral agents
(valacyclovir)
1/30/6
Anxiolytics
Alprazolam 1/31/8
Bromazepam 1/84/8
Dopamine agonists
• Pramiprexole 1/60/12a
• Ropirinol 1/181/12
• Terguride 1/99/12
Hormones
Calcitonin 1/11/4
Dehydroepiandrosteron 1/52/4
Prednisone 1/20/2
Hypnotics
Zolpidem 1/14/8
Interferon 1/28/4
Ketamine (intravenous) 1/20/0,5
Local anesthetics
(intravenous): Lidocaine
3/177/4
Neuroleptics: Ritanserin 1/24/16
Serotonin receptor
antagonists
Tropisetron 2/261/1
Odansetron 1/42/1
A pooled analysis was conducted in case of more than one study [16].
aPramiprexole was superior to placebo [33].
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Therefore, tramadol may be considered a step up from
over-the-counter simple analgesics for pain relief but has
a side effect profile similar to opioid agents but generally
less severe. No studies to date have examined the efficacy
of tapentadol, a drug with effects somewhat similar to
those of tramadol, but with mostly norepinephrine and
opioid agonist effect.
Cyclobenzaprine
Cyclobenzaprine, a muscle relaxant that is structurally
similar to the TCAs, is frequently used in North America
[9] but is unavailable in most European countries. A meta-
analysis of five RCTs with a total of 392 patients conducted
in the 1990s demonstrated that cyclobenzaprine-treated
patients were three times more likely to report overall im-
provement and moderate reductions in individual symp-
toms of pain and sleep problems compared with placebo
after 4 to 24 weeks [31]. A recent RCT with 36 patients
demonstrated superiority of low-dose cyclobenzaprine
over placebo for improving sleep after 8 weeks [32]. There-
fore, cyclobenzaprine may be considered a treatment op-
tion, but unfortunately evidence is limited.
Other prescribed fibromyalgia syndrome treatments with
use not supported by evidence
A wide array of drugs has failed to show superiority over
placebo (Table 3). It should be noted that these drugs
were examined mostly in either a single or few studies
and with small sample sizes.
Prescribed drugs that are not recommended for use in
the treatment of fibromyalgia syndrome?
Strong opioids
Worldwide, patients with FMS are prescribed strong opi-
oids in the absence of any published RCTs examining the
efficacy in FMS. With increasing concerns of the personal
and societal risks of opioid treatment for non-cancer
chronic pain conditions, this trend in opioid use is con-
cerning. In a nationally representative US dataset of com-
mercially insured individuals (245,758 patients with FMS),
11.3% (4% to 20%) received chronic daily opioid therapy
[34]. Similarly, in a study of about 7 million members of a
German statutory health insurance company, strong
opioids were prescribed for 11% with FMS [35]. The
German guideline search of literature identified only one
case series wherein the majority of patients worsened or
discontinued therapy because of side effects [36]. Opioid
use in FMS was associated with negative health-related
measures in a prospective cohort study of a Canadian inter-
disciplinary pain center [37]. Strong opioids were ranked as
the number one most harmful therapy in the German FMS
consumer reports [10]. The Canadian [13] and German
[15] guidelines unanimously strongly discouraged theprescription of strong opioids on the basis of lack of evi-
dence in the context of patient-related side effects and
risks to society with opioid prescription abuse. US authors
[38] rationalized that chronic opioid use is inappropri-
ate in the treatment of FMS because of the interaction
of unique pathophysiologic characteristics of FMS pa-
tients and effects associated with chronic opioid use.
The common practice of prescribing short-acting nar-
cotics on an ‘on demand’ basis to handle sudden in-
creases in painful symptoms has not yet been addressed
in either studies or practice guidelines but is generally
not recommended in guidelines for the treatment of
chronic, non-cancer pain [39].
Nonsteroidal anti-inflammatory drug
Nonsteroidal anti-inflammatory drug (NSAID) use is
prevalent for patients with FMS, either as a prescription
medication or as an on-demand over-the-counter prepar-
ation. Taking into consideration the increasing knowledge
of risks associated with chronic NSAID use, caution
should be exercised when advising patients with FMS.
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consumer reports were current users of NSAIDs [10],
whereas in the US, 36% report current use of ibuprofen
[9]. The German [15] guideline gave negative treatment
recommendations for NSAIDs on the basis of lack of
superiority compared with placebo after 1 to 8 weeks in
four RCTs with a total of 181 patients and also because
of potential side effects (for example, gastrointestinal
bleeding and cardiovascular risks) for long-term use.
However, in the US [9] and German [10] consumer re-
ports, a moderate benefit was attributed to NSAIDS,
mainly by patients with self-reported osteoarthritis and in-
flammatory rheumatic diseases [10]. It is noteworthy that
the latter patients were excluded in nearly all drug studies
in FMS, but fibromyalgia symptoms are prevalent in these
conditions. The primary use for NSAIDs remains for the
management of pain in rheumatic disease [40].
Drugs that held promise but without success
Sodium oxybate, an agent that affects dopamine release
by binding to the GABAB and gamma-hydroxybutyric
acid receptors, demonstrated efficacy in RCTs for FMS
symptoms [28]. However, this agent was denied approval
by the FDA on the grounds of safety and concerns about
diversion. Sodium oxybate was similarly refused approval
by the EMA as short- and long-term efficacy had not
been demonstrated in the EU population. The safety
profile of sodium oxybate is unfavorable with a high
frequency of central nervous system-related adverse
events, psychomotor effects that can pose a risk of
motor vehicle accidents, abuse, and diversion, and the
societal risk related to use as a date-rape drug [28].
Serotonin receptor agonists, such as tropisetron, have
been studied in four European RCTs, but a meta-
analysis demonstrated no significant superiority over
placebo [16]. The pharmaceutical companies of these
drugs have halted further trials (Späth, 2012, personal
communication).
Hope for the magic bullet?
Cannabinoids
Cannabinoid molecules have analgesic as well as sleep-
promoting effects. Nabilone, a synthetic tetrahydocannabi-
nol, has been tested in two small studies. In a 2-week
crossover study of 32 patients, nabilone was superior to
amitriptyline for reduction of sleep problems but with-
out differences in pain or quality of life [41]. In the
second study, nabilone was superior to placebo after 4
weeks in 40 patients for both pain and quality of life
[42]. There were frequent side effects, including vertigo
(47%), dizziness (35%), and nausea (31%). Nabilone did
not receive recommendation by the German guideline
[15], because of abuse potential [43]. The Canadian
guideline gave a weak recommendation for a trial ofpharmacologic cannabinoid, particularly in case of sleep
disturbance [13].
Growth hormone
Three RCTs of growth hormone (two studies compared
with placebo, one as add-on to multicomponent therapy
including antidepressants and tramadol) of 157 total
patients demonstrated benefits of growth hormone for
pain and fatigue after 9 to 18 months [44-46]. Cost and
potential side effects (metabolic changes, carpal tunnel
syndrome, and anemia) raise concerns about its use.
Quetiapine
Four double-blind controlled studies have explored the
efficacy of quetiapine, either alone or as an add-on treat-
ment, and only one study has been published to date.
The current available evidence suggests that quetiapine
may be useful, prompting further study [47]. In view of
side effects associated with the atypical neuroleptics
such as weight gain and metabolic changes [48], serious
concerns regarding their long-term use remain.
Naltrexone
In a randomized, double-blind, placebo-controlled, coun-
terbalanced, crossover study with 31 patients with FMS,
low-dose naltrexone was superior to placebo in the reduc-
tion of pain and depressed mood but not in the reduction
of fatigue and sleep problems [49]. Parallel-group RCTs
with larger sample sizes are needed to fully determine the
efficacy of this medication.
And many others
A search in ClinicalTrials.gov on 25 May 2013 revealed
studies that are active or completed with drug classes
such as antidepressants (agomelatine, paroxetine, and
trazodone), cannabinoids, dopamine agonists (droxidopa),
hormones (low-dose hydrocortisone), and hypnotics
(eszopilcone) as well as with new drug classes such as
AD337 (centrally acting non-opioid analgesic) and neuro-
tropines. Overall, it appears that many drugs are currently
undergoing testing of their efficacy in FMS. To date, all
agents under testing with available data show limited
promise at this time, and efficacy appears to be similar to
that seen with currently available agents.
Are any particular treatments better than the others?
The Oregon Health & Science University performed a
systematic review of comparative therapy through Octo-
ber 2010 by using published data, FDA medical and stat-
istical reviews, and dossiers submitted by pharmaceutical
companies. The authors found 47 eligible studies. Head-
to-head trials were few, and the evidence provided was
weak. Short-term treatment with immediate-release par-
oxetine was superior to amitriptyline in reducing pain
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to cyclobenzaprine and nortriptyline. Withdrawals due
to adverse events were similar. Using indirect-comparison
meta-analysis, the authors reported weak evidence that
there were differences between drugs for particular symp-
toms. Duloxetine was superior to milnacipran on out-
comes of pain, sleep disturbance, depressed mood, and
HRQOL. Both duloxetine and milnacipran were superior
to pregabalin for improvement in depressed mood,
whereas pregabalin was superior to milnacipran for im-
provement in sleep disturbance. Amitriptyline was similar
to duloxetine, milnacipran, and pregabalin on outcomes
of pain and fatigue, and data on the other outcomes were
insufficient. Although there were differences in specific
adverse events, they did not produce any differences in
overall withdrawals, adverse events, or withdrawals due to
adverse events [50].
Nüesch and colleagues [51] performed a systematic
search of the literature up to December 2011, including
102 trials with 14,982 subjects and eight active interven-
tions (TCAs, SSRIs, SNRIs, pregabalin, aerobic exercise,
balneotherapy, cognitive behavioral therapy, and multi-
component therapy) and examined the data by a
network analysis. Methodological quality and small
numbers introduced heterogeneity and inconsistency in
this analysis. When the analysis was restricted to large
trials with at least 100 patients per group, heterogeneity
was low and benefits for SNRIs and pregabalin com-
pared with placebo showed statistical significance but
only limited clinical relevance [51].
What should physicians and patients be mindful of when
drug therapy for fibromyalgia syndrome is considered?
Drug therapy is not a panacea for the care of patients with
symptoms of FMS. For many, who may have been through
various treatment trials, the final compromise may be the
limited use of prescription medications, on demand over-
the-counter agents, and focus toward non-pharmacologic
strategies. In those continuing drug treatments, many will
use a combination of drugs, generally in lower doses than
may be recommended by manufacturers. There is, how-
ever, no current evidence that patients benefit from drug
combinations, despite widespread use.
The best-studied drugs for treatment of FMS are ami-
triptyline, pregabalin, duloxetine, and milnacipran, lead-
ing to a recommendation as first-line treatment options
by two recent evidence- and interdisciplinary consensus-
based guidelines on FMS [13,14]. In general, the data on
their efficacy are robust even though the average incre-
mental benefit over placebo is small [16,17,19-22]. The
evidence for amitriptyline’s beneficial effect is not as
substantial as the others but should be taken in context
with decades of its perceived success in FMS treatment
[19]. At this time, the data suggest that there are notsubstantial differences in efficacy between duloxetine,
milnacipran, and pregabalin. Rather, the evidence sug-
gests that the majority of medications can provide an
improvement in pain of 30% in half of the patients tak-
ing the medication and that improvements in pain of
50% are seen in a third of patients. These observed bene-
fits do not translate into global improvement in well-being
as measured by Short Form Health Survey-36 (SF-36)
or the Health Assessment questionnaire. Despite treat-
ment, physical health perceptions remain substantially
lower (1.5 standard deviations) in FMS than in the
general population, and scores of patients with FMS are
essentially equivalent to those seen in patients on
chronic dialysis [52]. Cyclobenzaprine, other SSRI anti-
depressants (fluoxetine and paroxetine), and tramadol
with and without acetaminophen can be regarded as
second-line treatment options. Therapies with other
drugs (for example, nabilone and quetiapine) remain
experimental at this time.
Drug therapy should be initiated with small dosages
and with gradual upward titration. We recommend
starting amitriptyline 10 mg at night, pregabalin 50 to
100 mg at night, duloxetine 30 mg daily, and milnaci-
pran 50 mg in the morning. The highest recommended
dosages are amitriptyline 10 to 50 mg/daily, pregabalin
300 to 450 mg/daily, duloxetine 60 mg/daily, and milna-
cipran 100 mg/daily. Patients should be monitored regu-
larly for efficacy and tolerability, whether by visit, by
phone, or by email, especially within the first weeks of
treatment. Responses should be expected within 2 to 4
weeks once recommended dosage has been achieved
[21]. Treatment should be continued in treatment re-
sponders only. Medications that are not providing the
patient benefit should be discontinued rather than sup-
plemented by other drugs in pursuit of higher benefits
by ‘combining’ drug treatments.
Contrary to popular perception, drug treatments
should be recommended with reservation because of
limited efficacy and side effect potential. Though not
supported by RCTs, two recent guidelines strongly
discourage drug therapy as a single management strategy
for FMS. Drug therapy may be added to self-management
strategies that include aerobic exercise or psychological
therapies (or both) but with the ideal objective that long-
term management will be achieved with no or minimal
drug therapy [13,14]. Shared decision-making by patients
and physicians is required to provide optimal health care
for patients with FMS. Drug choices should target the
most prominent comorbid symptoms. Amitriptyline or
pregabalin could be preferred for those with sleep distur-
bances, duloxetine for major depression, and duloxetine
or pregabalin for general anxiety disorder [17,20,22]. Pa-
tients with comorbid rheumatic disease may consider
tramadol or either duloxetine or tramadol for comorbid
Note: This article is part of the series on New perspectives in
fibromyalgia, edited by Daniel Clauw. Other articles in this series
can be found at http://arthritis-research.com/series/fibromyalgia
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dysfunction by SSRI and weight gain by TCAs and prega-
balin) and contraindications (for example, SNRIs in case
of severe liver damage and pregabalin for professional
drivers) should be reviewed and carefully considered.
Medication cost and local status of approval may be an
important issue, in particular in choosing between generic
amitriptyline and the other patented first-line agents [20].
Both physicians and patients should have realistic ex-
pectations about the potential benefit of these drugs. Al-
though patients may initially experience symptom relief
with good tolerance, the majority will ultimately discon-
tinue therapy because of inadequate response or unaccept-
able side effects [17,21,22]. Reduced dosing for pregabalin
may allow better tolerability, although this generally does
not apply for duloxetine or milnacipran. Taking
alpha-2-delta ligands at night or SNRIs with food and at a
low initial dose helps improve tolerability. Placebo and
nocebo responses play an important role in the positive
and negative (dropout rate) effects of drugs in FMS, and
estimates are that these effects account for up to 60% of
measured drug efficacy and harms [27,28]. The deliberate
use of psychological strategies underlying the placebo
response, such as promoting positive treatment expecta-
tions and establishing a positive therapeutic relationship
and regular health-care contact, can likely bolster the
positive effects of drug treatment. Similarly, open discus-
sion of previous drug experiences, exploring potential un-
realistic fears, and regular patient contact may attenuate
the nocebo response. Important points to consider in the
drug therapy of FMS-patients are summarized as follows:
 Drug therapy is not mandatory.
 Shared decision-making for or against drug therapy
 Tailored selection of drugs according to– Key symptoms beyond pain (fatigue, sleep
problems)
– Psychological comorbidities (depressive or
anxiety disorder or both)
– Physical comorbidities (rheumatic disease)
– Contraindications
– Individual importance of frequent side effects
(for example, weight gain)
 Augment placebo and reduce nocebo response.
 Start low, go slow.
 Monitor for efficacy, tolerability, and safety.
 Progressive treatment reduction in responders
 Consider drug holidays.
 Promote long-term drug-free self-management of
the patient.
Conclusions
Drug therapy as the sole strategy for the management of
patients with FMS should be discouraged. Taking intoconsideration the modest effect of currently available
drugs, high prevalence of adverse effects, and poor rec-
ord of continued use, the health-care community must
be vigilant in adhering to responsible prescribing prac-
tices and carefully monitor patients for both efficacy and
side effects.Abbreviations
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